AR016500A1 - Proceso para la preparacion de derivados de acido hidroxi-pirrolidinil-hidroxamico que son agonistas opiodes del kappa receptor e intermediarios utiles. - Google Patents
Proceso para la preparacion de derivados de acido hidroxi-pirrolidinil-hidroxamico que son agonistas opiodes del kappa receptor e intermediarios utiles.Info
- Publication number
- AR016500A1 AR016500A1 ARP990102917A ARP990102917A AR016500A1 AR 016500 A1 AR016500 A1 AR 016500A1 AR P990102917 A ARP990102917 A AR P990102917A AR P990102917 A ARP990102917 A AR P990102917A AR 016500 A1 AR016500 A1 AR 016500A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- hydrogen
- acid derivatives
- hydroxamic acid
- alkyloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un método para preparar derivados de ácido hidroxámico de formula (I) y las sales de los mismos, donde A es hidrogeno, hidroxi, o OY donde Y es un grupoprotector hidroxi: Ar es fenilo opcionalmente substituido con uno o más (preferiblemente hasta tres) sustituyentes seleccionados de halo, hidroxi, C1-4 alquil,C1-4 alquiloxi, CF3, C1-4 alcoxi-C1-4 alquiloxi y carboxi-C1-4 alquiloxi; X es fenilo, naftil, bifenilo, indanil, benzofuranil, benzotiofenilo, 1-tetraluno-6-il, C1-4 alquilendioxi, piridil, furil, y tienil, estos grupos estando opcionalmente sustituidos con hasta tres sustituyentes seleccionados de halo, C1-4alquil, C1-4 alcoxi, hidroxi, NO2, CF3 y SO2CH3; y R3 es hidrogeno, C1-4 alquilo un grupo protector hidroxi. Compuestos Intermediarios utiles para prepararcompuestos de formula I son también provistos. Los derivados de ácido hidroxámico de fnormula (I), donde A es hidrogeno o hidroxi y R es hidrogeno o C1-4alquil, exhiben actividad agonista significativa hacia los receptoresopioides kappa. Estos agonistas son particularmente utiles como un agente analgésico enmamíferos, especialmente humanos. Ellos son también utiles como antiinflamatorios, diuréticos, anestésicos o agentes neuroprotectores, o un agente para eltratamiento de ataques cardíacos o enfermedades funcionales de los intestinos tales como dolor abdominal, para el tratamiento de un sujeto mamíferoespecialmente sujeto humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9763398P | 1998-08-24 | 1998-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016500A1 true AR016500A1 (es) | 2001-07-04 |
Family
ID=22264376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102917A AR016500A1 (es) | 1998-08-24 | 1999-06-17 | Proceso para la preparacion de derivados de acido hidroxi-pirrolidinil-hidroxamico que son agonistas opiodes del kappa receptor e intermediarios utiles. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6031114A (es) |
| EP (1) | EP0982297A3 (es) |
| JP (1) | JP3245578B2 (es) |
| KR (1) | KR100338916B1 (es) |
| CN (1) | CN1245799A (es) |
| AR (1) | AR016500A1 (es) |
| AU (1) | AU4466599A (es) |
| BR (1) | BR9902525A (es) |
| CA (1) | CA2277242A1 (es) |
| HU (1) | HUP9901944A3 (es) |
| ID (1) | ID23462A (es) |
| IL (1) | IL130429A0 (es) |
| IN (1) | IN190844B (es) |
| PL (1) | PL334144A1 (es) |
| RU (1) | RU2163235C1 (es) |
| TR (1) | TR199901546A3 (es) |
| YU (1) | YU31499A (es) |
| ZA (1) | ZA994285B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1461317A2 (en) * | 2001-04-30 | 2004-09-29 | Pfizer Products Inc. | Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists |
| AU2003269399A1 (en) * | 2002-11-01 | 2004-05-25 | Pfizer Products Inc. | Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination |
| US7744750B2 (en) * | 2005-11-17 | 2010-06-29 | Exxonmobil Chemical Patents Inc. | Process for reducing Bromine Index of hydrocarbon feedstocks |
| US8057664B2 (en) * | 2005-11-17 | 2011-11-15 | Exxonmobil Chemical Patents, Inc. | Process for reducing bromine index of hydrocarbon feedstocks |
| US7517824B2 (en) * | 2005-12-06 | 2009-04-14 | Exxonmobil Chemical Company | Process for steam stripping hydrocarbons from a bromine index reduction catalyst |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0132001B1 (ko) * | 1994-05-21 | 1998-04-17 | 강박광 | 신규한 치환된 이미다졸 유도체 |
| IL117440A0 (en) * | 1995-03-31 | 1996-07-23 | Pfizer | Pyrrolidinyl hydroxamic acid compounds and their production process |
| MX9701042A (es) * | 1996-02-07 | 1998-05-31 | Pfizer | Compuestos del acido hidroxamico. |
| TNSN97092A1 (ar) * | 1996-09-18 | 1999-12-31 | Agouron Pharma | مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة. |
-
1999
- 1999-06-10 EP EP99304531A patent/EP0982297A3/en not_active Withdrawn
- 1999-06-10 IL IL13042999A patent/IL130429A0/xx unknown
- 1999-06-11 HU HU9901944A patent/HUP9901944A3/hu unknown
- 1999-06-15 RU RU99113363/04A patent/RU2163235C1/ru not_active IP Right Cessation
- 1999-06-17 AR ARP990102917A patent/AR016500A1/es not_active Application Discontinuation
- 1999-06-17 IN IN883DE1999 patent/IN190844B/en unknown
- 1999-06-29 JP JP18308699A patent/JP3245578B2/ja not_active Expired - Fee Related
- 1999-06-30 ZA ZA9904285A patent/ZA994285B/xx unknown
- 1999-06-30 CA CA002277242A patent/CA2277242A1/en not_active Abandoned
- 1999-07-01 KR KR1019990026361A patent/KR100338916B1/ko not_active IP Right Cessation
- 1999-07-01 BR BR9902525-6A patent/BR9902525A/pt not_active IP Right Cessation
- 1999-07-01 PL PL99334144A patent/PL334144A1/xx unknown
- 1999-07-01 ID IDP990637D patent/ID23462A/id unknown
- 1999-07-01 YU YU31499A patent/YU31499A/sh unknown
- 1999-07-01 CN CN99108932A patent/CN1245799A/zh active Pending
- 1999-07-02 TR TR1999/01546A patent/TR199901546A3/tr unknown
- 1999-08-16 US US09/374,869 patent/US6031114A/en not_active Expired - Fee Related
- 1999-08-23 AU AU44665/99A patent/AU4466599A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HU9901944D0 (en) | 1999-08-30 |
| HUP9901944A3 (en) | 2001-10-29 |
| IL130429A0 (en) | 2000-06-01 |
| KR20000016898A (ko) | 2000-03-25 |
| EP0982297A3 (en) | 2001-08-01 |
| JP2000072744A (ja) | 2000-03-07 |
| RU2163235C1 (ru) | 2001-02-20 |
| TR199901546A2 (xx) | 2000-04-21 |
| CN1245799A (zh) | 2000-03-01 |
| CA2277242A1 (en) | 2000-02-24 |
| IN190844B (es) | 2003-08-23 |
| ID23462A (id) | 2000-04-27 |
| EP0982297A2 (en) | 2000-03-01 |
| YU31499A (sh) | 2002-11-15 |
| ZA994285B (en) | 2001-01-02 |
| TR199901546A3 (tr) | 2000-04-21 |
| HUP9901944A2 (hu) | 2000-06-28 |
| JP3245578B2 (ja) | 2002-01-15 |
| US6031114A (en) | 2000-02-29 |
| KR100338916B1 (ko) | 2002-05-30 |
| AU4466599A (en) | 2000-03-09 |
| BR9902525A (pt) | 2000-05-02 |
| PL334144A1 (en) | 2000-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009357A1 (es) | Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa | |
| KR830006174A (ko) | 기관지 항경련성 화합물 제조방법 | |
| AR006705A1 (es) | Compuestos de 3-[4-(2-fenil-indol-1-ilmetil)-fenil]-acrilamida y 2-fenil-1-[4-(amino-1-il-alqu-1-inil)-bencil]-1h-indol-5-ol, metodo para preparar medicamentos y composiciones farmaceuticas que los contiene | |
| ES2141688B1 (es) | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. | |
| ES2124612T3 (es) | Dihidrodibenzo(b,f)azepinas, substituidas, metodo para su preparacion, su utilizacion en el tratamiento de diversos trastornos del sistema nervioso central y composiciones farmaceuticas que las contienen. | |
| BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
| AR012264A1 (es) | Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada | |
| BR0009297A (pt) | Composto, processo para produzir o mesmo,composição farmacêutica, método paraantagonizar hormÈnio de liberação degonadotropina em um mamìfero, e, uso de umcomposto | |
| IT1137640B (it) | Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo | |
| EA200500286A1 (ru) | Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) | |
| NZ548689A (en) | Antiparasitic composition containing an organic amine salt of closantel | |
| AR002729A1 (es) | Compuesto de acido pirrolidinil hidroxamica, procedimiento e intermediario para su produccion, composicion farmaceutica que lo contiene y procedimientopara producir el intermediario. | |
| AR007021A1 (es) | Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos | |
| ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| AR016500A1 (es) | Proceso para la preparacion de derivados de acido hidroxi-pirrolidinil-hidroxamico que son agonistas opiodes del kappa receptor e intermediarios utiles. | |
| ES2032384T3 (es) | Procedimiento para preparar derivados de carboxamidas. | |
| PT87854B (pt) | Processo para a preparacao de derivados de tio-ureia | |
| BR0008778A (pt) | Análogos de prostaglandinas seletivos para fpc16 insaturados | |
| ES2183492T3 (es) | Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| KR900014306A (ko) | 테트라하이드로나프탈렌 유도체 | |
| ES2068813T3 (es) | Derivados cefem de tiadiazolilacetamida. | |
| AR035660A1 (es) | Compuestos 3,10-dibromo-8-cloro-11h-benzo[5,6]ciclohepta[1,2-b]piridin-11-il-4-piperidinilos o sus sales farmaceuticamente aceptables, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un procedimiento para producir un compuesto intermediario para produ | |
| ES2055440T3 (es) | Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen. | |
| ES2151222T3 (es) | Compuestos del acido hidroxamico como agonistas de receptor opiaceo kappa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |